TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for New Highly Resistant TB Treatment
The NPAP is designed for patients in countries where regulatory approval or other access mechanisms for pretomanid are not yet
Press Releases
A Conversation with Mitchell Warren
We spoke with Mitchell Warren, president of the TB Alliance Stakeholders Association (SHA) about what it means for TB Alliance
COVID-19: a message of solidarity on World TB Day 2020
Since 1982, those engaged in the fight against tuberculosis (TB) have observed 24 March as World TB Day, to commemorate
TB Alliance Names Dr. Daniel Everitt Vice President and Chief Medical Officer
NEW YORK (February 12, 2020)—TB Alliance has appointed Dr. Daniel Everitt to the position of Vice President and Chief Medical
Jane Griffiths Joins TB Alliance Board of Directors
NEW YORK (February 3, 2020)—TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has
TB Research Funding Continues to Fall Short
January 30, 2020—The 2019 G-FINDER report indicates that global investment in tuberculosis (TB) research and development (R&D) levels remain far
TB Alliance Partners with ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments against Tuberculosis
NEW YORK (January 29, 2020)—TB Alliance and partners announced the launch of the ERA4TB (European Regimen Accelerator for Tuberculosis) project
New Research Assesses Efficacy of Different Doses of Linezolid, Key Medicine Used in Regimens that Treat Drug-Resistant Tuberculosis
NEW YORK (January 27, 2020)—New peer-reviewed research has evaluated the efficacy of different doses and schedules of linezolid for the treatment
TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China
NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned
Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.